Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months - a post-hoc analysis of a randomised trial

被引：0
|
作者：
Wong, S. [1 ]
Miller, K. [2 ]
Smith, M. R. [3 ]
Dearnaley, D. [4 ]
Dogliott, L. [5 ]
Egerdie, B. [6 ]
Fizazi, K. [7 ]
Kueppers, F. [8 ]
Montes De Oca, L. [9 ]
Morote, J. [10 ]
Pavlik, I. [11 ,12 ]
Sieber, P. [13 ]
Tammel, T. J. [14 ]
Van Poppel, H. [15 ]
Wirth, M. [16 ]
Ye, Z. [17 ]
Braun, A. [17 ]
机构：
[1] Western Hosp, Footscray, Vic, Australia
[2] Charite, Berlin, Germany
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[5] Osped San Luigi Gonzaga, Orbassano, TO, Italy
[6] Urol Associates, Urol Med Res, Kitchener, ON, Canada
[7] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[8] Canterbury Urol Res Trust, Christchurch, New Zealand
[9] Ctr Diagnost Urol, Buenos Aires, DF, Argentina
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Gen Teaching Hosp, Urol Clin, Prague, Czech Republic
[12] Fac Med 1, Prague, Czech Republic
[13] Urol Associates Lancaster, Lancaster, PA USA
[14] Tampere Univ Hosp, Tampere, Finland
[15] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[16] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[17] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [1] Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer
    Howard, Lauren E.
    Moreira, Daniel M.
    De Hoedt, Amanda
    Aronson, William J.
    Kane, Christopher J.
    Amling, Christopher L.
    Cooperberg, Matthew R.
    Terris, Martha K.
    Freedland, Stephen J.
    BJU INTERNATIONAL, 2017, 120 (5B) : E80 - E86
  • [2] The impact of bone metastases on pain: post-hoc analysis of a phase III study of denosumab in men with non-metastatic Castration-Resistant Prostate Cancer (CRPC)
    Saad, F.
    Patrick, D. J.
    Smith, M.
    Cleeland, C.
    Fallowfield, L.
    Tombal, B.
    Oudard, S.
    Shore, N.
    Marx, G.
    Coleman, R.
    Gomez-Veiga, F.
    Damiao, R.
    Zhou, Y.
    Arellano, J.
    Braun, A.
    Qian, Y.
    BJU INTERNATIONAL, 2013, 111 : 38 - 38
  • [3] Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC)
    Srinivas, S.
    Harshman, L. C.
    Feldman, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and ≤ 6 months.
    Schlack, K.
    Smith, M. R.
    Shore, N. D.
    Tammela, T. L. J.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M. -A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 223 - 223
  • [5] PREDICTORS OF TIME TO METASTASIS IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Moreira, Daniel
    Howard, Lauren
    Sourbeer, Katie
    Kundich, Robert
    Kane, Christopher
    Aronson, William
    Terris, Martha
    Cooperberg, Matthew
    Amling, Christopher
    Freedland, Stephen
    JOURNAL OF UROLOGY, 2014, 191 (04): : E921 - E921
  • [6] Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
    Whitney, Colette A.
    Howard, Lauren E.
    Freedland, Stephen J.
    DeHoedt, Amanda M.
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Daskivich, Timothy J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (02) : 252 - 260
  • [7] Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
    Colette A. Whitney
    Lauren E. Howard
    Stephen J. Freedland
    Amanda M. DeHoedt
    Christopher L. Amling
    William J. Aronson
    Matthew R. Cooperberg
    Christopher J. Kane
    Martha K. Terris
    Timothy J. Daskivich
    Prostate Cancer and Prostatic Diseases, 2019, 22 : 252 - 260
  • [8] IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Whitney, Colette
    Howard, Lauren
    Freedland, Stephen
    Amling, Christopher
    Aronson, William
    Cooperberg, Matthew
    Kane, Christopher
    Terris, Martha
    Daskivich, Timothy
    JOURNAL OF UROLOGY, 2017, 197 (04): : E59 - E60
  • [9] Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
    A H Bryce
    J J Alumkal
    A Armstrong
    C S Higano
    P Iversen
    C N Sternberg
    D Rathkopf
    Y Loriot
    J de Bono
    B Tombal
    S Abhyankar
    P Lin
    A Krivoshik
    D Phung
    T M Beer
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 221 - 227
  • [10] Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
    Bryce, A. H.
    Alumkal, J. J.
    Armstrong, A.
    Higano, C. S.
    Iversen, P.
    Sternberg, C. N.
    Rathkopf, D.
    Loriot, Y.
    de Bono, J.
    Tombal, B.
    Abhyankar, S.
    Lin, P.
    Krivoshik, A.
    Phung, D.
    Beer, T. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (02) : 221 - 227
12345